How Cytokine Networks Fuel Inflammation: Toward a Cytokine-based Disease Taxonomy

Overview

Journal Nat Med

Specialties General Medicine
Molecular Biology

Date 2013 Jul 10

PMID 23836224

Citations 176

Authors

Georg Schett

Dirk Elewaut

Iain B McInnes

Jean-Michel Dayer

Markus F Neurath

Affiliations

Soon will be listed here.

Citing Articles

Biomaterials for Modulating the Immune Microenvironment in Rheumatoid Arthritis.

Wang Q, Ji J, Huang D, Gao C BME Front. 2025; 6:0102.

PMID: 40065832 PMC: 11893043. DOI: 10.34133/bmef.0102.

An Attomolar-Level Optical Device for Monitoring Receptor-Analyte Interactions Without Functionalization Steps: A Case Study of Cytokine Detection.

Cennamo N, Arcadio F, Marzano C, Pitruzzella R, Seggio M, Pesavento M Sensors (Basel). 2025; 25(3).

PMID: 39943569 PMC: 11820668. DOI: 10.3390/s25030930.

Nanosystems for modulation of immune responses in periodontal therapy: a mini-review.

Acharya A, Hegde U, Acharya S Front Dent Med. 2025; 5:1509775.

PMID: 39917718 PMC: 11797770. DOI: 10.3389/fdmed.2024.1509775.

Folic acid-modified ginger-derived extracellular vesicles for targeted treatment of rheumatoid arthritis by remodeling immune microenvironment via the PI3K-AKT pathway.

Han R, Zhou D, Ji N, Yin Z, Wang J, Zhang Q J Nanobiotechnology. 2025; 23(1):41.

PMID: 39849554 PMC: 11756199. DOI: 10.1186/s12951-025-03096-5.

Spiro thiochromene-oxindoles as novel anti-inflammatory agents: design, sustainable synthesis, and evaluations.

Manju , Raigar A, Saini K, Jyoti N, Kapavarapu R, Guleria A RSC Adv. 2025; 15(1):261-275.

PMID: 39758897 PMC: 11694626. DOI: 10.1039/d4ra07990f.

References

Brouckaert P, Spriggs D, Demetri G, Kufe D, Fiers W . Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon gamma. J Exp Med. 1989; 169(6):2257-62. PMC: 2189347. DOI: 10.1084/jem.169.6.2257. View

Dinarello C, Cannon J, Wolff S, Bernheim H, Beutler B, Cerami A . Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med. 1986; 163(6):1433-50. PMC: 2188124. DOI: 10.1084/jem.163.6.1433. View

McInnes I, Schett G . The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011; 365(23):2205-19. DOI: 10.1056/NEJMra1004965. View

Jones S, Scheller J, Rose-John S . Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 2011; 121(9):3375-83. PMC: 3163962. DOI: 10.1172/JCI57158. View

Probert L, Eugster H, Akassoglou K, Bauer J, Frei K, Lassmann H . TNFR1 signalling is critical for the development of demyelination and the limitation of T-cell responses during immune-mediated CNS disease. Brain. 2000; 123 ( Pt 10):2005-19. DOI: 10.1093/brain/123.10.2005. View

Leppkes M, Becker C, Ivanov I, Hirth S, Wirtz S, Neufert C . RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology. 2008; 136(1):257-67. DOI: 10.1053/j.gastro.2008.10.018. View

Wekerle H, Flugel A, Fugger L, Schett G, Serreze D . Autoimmunity's next top models. Nat Med. 2012; 18(1):66-70. DOI: 10.1038/nm.2635. View

OShea J, Kontzias A, Yamaoka K, Tanaka Y, Laurence A . Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013; 72 Suppl 2:ii111-5. PMC: 3616338. DOI: 10.1136/annrheumdis-2012-202576. View

Hueber W, Sands B, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins P . Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012; 61(12):1693-700. PMC: 4902107. DOI: 10.1136/gutjnl-2011-301668. View

10.

Houslay M, Schafer P, Zhang K . Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today. 2005; 10(22):1503-19. DOI: 10.1016/S1359-6446(05)03622-6. View

11.

Nickoloff B . Cracking the cytokine code in psoriasis. Nat Med. 2007; 13(3):242-4. DOI: 10.1038/nm0307-242. View

12.

Neogi T . Clinical practice. Gout. N Engl J Med. 2011; 364(5):443-52. DOI: 10.1056/NEJMcp1001124. View

13.

Neurath M, Finotto S, Glimcher L . The role of Th1/Th2 polarization in mucosal immunity. Nat Med. 2002; 8(6):567-73. DOI: 10.1038/nm0602-567. View

14.

Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A . A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology. 2004; 126(4):989-96. DOI: 10.1053/j.gastro.2004.01.012. View

15.

Sandborn W, Gasink C, Gao L, Blank M, Johanns J, Guzzo C . Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012; 367(16):1519-28. DOI: 10.1056/NEJMoa1203572. View